Objective: To examine the utility of palpation-guided fine-needle aspiration cytology (pgFNAC) in the context of clinically palpable but radiologically occult breast abnormalities in this era of digital mammography and high sensitivity ultrasound. Methods: Women undergoing pgFNAC from January 2005 to December 2007 were identified from the histopathology database and correlated with clinical and radiological findings recorded prospectively in electronic patient records. Results: 142 cases matching our selection criteria were identified with a mean age of 43 (SD ±13.7) years; 83 patients had focal lumps and 59 had non-focal lumpiness. In the latter, pgFNAC showed C1 cytology in 45 (76.3%), C2 in 13 (22%) and C3 in 1 (1.7%) patient. In 83 patients with a focal discrete lump, pgFNAC revealed C1 cytology in 65 (78.3%), C2 in 14 (16.9%), and 2 patients each had C3 and C4 cytology. Core biopsy was undertaken in the latter 4 patients, invasive cancer was found in 1 patient each with C3 and C4 cytology and benign pathology in the rest. To date, none of the patients discharged has developed pre-malignant or malignant lesions in the ipsilateral breast. Conclusion: In patients presenting with clinically palpable but radiologically occult breast abnormality, pgFNAC can identify those who need further investigation or who can be safely discharged.

Keywords:
Radiology, Fine needle aspiration cytology, Biopsy, Breast neoplasms
1.
National Institute of Clinical Excellence: Guidance on Cancer Services. Improving Outcomes in Breast Cancer. London, National Institute of Clinical Excellence, 2002, http://www.nice.org.uk/nicemedia/live/10887/28763/28763.pdf.
2.
Morrow M: Physical examination of the breast; in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, Lippincott Williams & Wilkins, 2004, pp 33–36.
3.
NHSBSP: Guidelines for Pathology Reporting in Breast Disease. London, NHSBSP, 2005, http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58.html.
4.
Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D: Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med 2003;139:274–284.
5.
Sterns EE: Age-related breast diagnosis. Can J Surg 1992;35:41–45.
6.
Paramagul CP, Helvie MA, Adler DD: Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology 1995;195:231–234.
7.
Evans WP, Warren Burhenne LJ, Laurie L, O’Shaughnessy KF, Castellino RA: Invasive lobular carcinoma of the breast: mammographic characteristics and computer-aided detection. Radiology 2002;225:182–189.
8.
Selinko VL, Middleton LP, Dempsey PJ: Role of sonography in diagnosing and staging invasive lobular carcinoma. J Clin Ultrasound 2004;32:323–332.
9.
Patel JJ, Gartell PC, Smallwood JA, Herbert A, Royle G, Buchanan R, et al: Fine needle aspiration cytology of breast masses: an evaluation of its accuracy and reasons for diagnostic failure. Ann R Coll Surg Engl 1987;69:156–159.
10.
Morrow M, Wong S, Venta L: The evaluation of breast masses in women younger than forty years of age. Surgery 1998;124:634–640, discussion 40–41.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.